Paxiban
On the Bulgarian pack: Паксибан 2,5 mg филмирани таблетки
2.5 mg · film - coated tablets
- Prescription only
- Blood, clotting and anaemia
- Active substance
- Apixaban
- Used in
- Blood, clotting and anaemia
- Made by
- Nobel Pharma EOOD
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet read the official leaflet for this product. The exact uses and dose are in the leaflet inside the pack. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (apixaban). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Apixaban is a selective inhibitor of FXa.
It does not require antithrombin III for antithrombotic activity.
Apixaban is metabolized mainly via CYP3A4 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2.
Apixaban is eliminated in both urine and feces.
Food does not affect the bioavailability of apixaban.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-02-03
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (apixaban). It describes the substance, not this Bulgarian product — its uses and doses can differ.
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.
- ELIQUIS is contraindicated in patients with the following conditions: Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1) ] Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [see Adverse Reactions (6.1) ] Active pathological bleeding (4) Severe hypersensitivity to ELIQUIS (4)
Most common adverse reactions (>1%) are related to bleeding.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States6 matching products
European UnionNo exact match for this strength and form
Spain50 matching products
- ELIQUIS 2,5 mg · comprimido recubierto con película4 makers
- AKADASAY 2,5 mg · comprimido recubierto con película
- APICASSA 2,5 mg · comprimido recubierto con película
- APICLOT 2,5 mg · comprimido recubierto con película
- APIXABAN ACCORD 2,5 mg · comprimido recubierto con película
- APIXABAN ADAMED 2,5 mg · comprimido recubierto con película
- APIXABAN ALMUS 2,5 mg · comprimido recubierto con película
- APIXABAN ALTER GENERICOS 2,5 mg · comprimido recubierto con película
Canada23 matching products
Netherlands38 matching products
- Apixaban TOWA Pharmaceutical 2 2,5 mg · filmomhulde tablet3 makers
- Abatixent 2 2,5 mg · filmomhulde tablet
- Apilion 2 2,5 mg · filmomhulde tablet
- Apixaban 1A Pharma 2 2,5 mg · filmomhulde tablet
- Apixaban Abdi 2 2,5 mg · filmomhulde tablet
- Apixaban Accord 2 2,5 mg · filmomhulde tablet
- Apixaban Amarox 2 2,5 mg · filmomhulde tablet
- Apixaban Aristo 2 2,5 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Nobel Pharma EOOD · Bulgaria |
|---|---|
| Active substance | Apixaban |
| Used in | Blood, clotting and anaemia |
| Strength | 2.5 mg |
| Form | film - coated tablets |
| Pack sizes | 10 · 20 · 56 · 60 |
| Classification | B01AF02 · Blood, clotting and anaemia |
| Name in the register | Паксибан 2,5 mg филмирани таблетки |
| Reg. no. | 20240131 |
Source: Bulgarian Drug Agency register · 2026-08-01 · not reviewed by a clinician
Източник: Изпълнителна агенция по лекарствата (ИАЛ). The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- film - coated tablets3 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.